Annexon Announced Topline Results From A Real-world Evidence Study Supporting Anx005 As A Potential Treatment For Guillain-barré Syndrome
Annexon Announced Topline Results From A Real-world Evidence Study Supporting Anx005 As A Potential Treatment For Guillain-barré Syndrome
Annexon宣佈了一項真實世界證據研究的頂線結果，支持Anx005作爲吉蘭-巴雷綜合徵的潛在治療方案。
- Real-World Evidence Study Strengthens the Body of Evidence Supporting ANX005 for Treatment of GBS
- ANX005 Phase 3 Population Was Matched 1:1 on Prespecified Criteria with Patients in International GBS Outcomes Study (IGOS)
- Matched Cohort Study Showed Early and Greater Benefits of ANX005 over IVIg or PE in Muscle Strength and Functional Outcomes Across Multiple Measurements
- 真實世界證據研究加強了支持ANX005治療GBS的證據基礎
- ANX005第三階段的受試者在預先規定的標準下與國際GBS結果研究(IGOS)中的患者進行了1:1匹配
- 匹配隊列研究顯示，ANX005在肌肉力量和功能結果的多個測量指標上的早期和更大益處，相較於IVIg或市盈率
資訊熱榜
更新時間